米国のアニマルヘルスの市場規模・シェア・動向分析レポート：動物タイプ別、製品別、ワクチンタイプ別、疾患別、投与経路別、流通チャネル別、セグメント別予測（2025年～2030年）

米国のアニマルヘルス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国のアニマルヘルスの市場規模は、2025年～2030年にCAGR7.97％を記録し、2030年までに197億7,000万米ドルに達すると予測されています。

この市場は主に、動物の数と飼育率の増加、動物への支出の増加、予防的動物ヘルスケアへの注目の高まり、獣医学の進歩、革新的な製品を発売するための動物用医薬品への研究開発投資の増加によって牽引されています。例えば、2024年11月、BimedaはFDA認可の肉牛および非泌乳牛用寄生虫駆除剤であるMoxiSolv Injection（モキシデクチン）を、便利で飛散しない500mLのプラスチックボトルで発売しました。

さらに、人獣共通感染症の増加、家畜人口の増加、予防医療への関心の高まり、畜産支出の増加もこの業界を牽引しています。米国では畜産人口が増加しており、食肉生産用に飼育されている牛、羊、豚、家禽が大幅に増加しています。例えば、World Markets and Tradeレポートによると、米国対外農業庁の家畜・家禽類に関する報告書では、2024年1月現在、米国の牛頭数は8,780万頭、豚頭数は7,497万頭となっています。このように多くの家畜がいるため、健康と生産性を維持するための包括的な獣医学的ケアと医療介入が必要となります。

加えて、年間700億米ドル以上をもたらす畜産業の経済的重要性により、利害関係者は疾病による潜在的損失を軽減するため、健康管理を優先するようになりました。高品質の牛肉や乳製品に対する消費者の需要の高まりや、持続可能な農法に対する意識の高まりも、牛の健康管理ソリューションの採用に重要な役割を果たしています。政府の支援による取り組みや、農村部における獣医サービスの強化は、このセクターをさらに強化し、その継続的な拡大を確実なものにしています。

さらに、薬用飼料添加物の承認が増加していることも、家畜の健康と生産効率を向上させることで市場を大きく牽引しています。例えば、2024年6月、FDAはElancoのメタン削減飼料添加物Bovaer（3-NOP）を泌乳牛用に承認しました。Bovaerはメタン排出量を牛1頭当たり30％削減することができ、100万頭の牛が使用した場合、年間28万5,000台の自動車を道路から排除するのと同等の排出量を削減できる可能性があります。この技術革新は、炭素市場を通じて酪農家に金銭的インセンティブを与え、持続可能な取り組みと世界の気候変動目標の達成を支援します。dsm-Firmenichとの提携により、エランコは北米全域でBovaerを販売し、持続可能な農業の実践と酪農産業の競争力強化に貢献します。

同様に、動物用医薬品の急速な進歩は、この業界に有利な機会をもたらしています。動物用医薬品の開発により、多くの種類の動物の病気や疾患に対して、より集中的で効率的な治療法が開発されています。さらに、革新的な動物用医薬品の需要は、動物にとってより良い結果をもたらし、副作用を減少させ、有効性を高める新薬や治療法によって牽引されています。例えば、2024年9月、メルクアニマルヘルスは、ネコ白血病ウイルス（FeLV）用の初のRNAワクチンであるNOBIVAC NXT FeLVを発売することにより、NOBIVAC NXTワクチンのプラットフォームを拡大しました。この革新的なワクチンは、一般的なネコの感染症であるFeLVに対する最適化された防御を提供し、全国の動物病院で使用できるようになる予定です。同様に、2024年6月、ビメダは、馬、犬、猫の炎症とアレルギー症状の治療に使用される、FDAが承認した初のジェネリック医薬品であるフルメタゾンBimasoneを発売しました。

米国のアニマルヘルス市場レポートのハイライト

• 製品別では、医薬品セグメントが2024年に最も高い売上シェアを占めました。しかし、生物製剤セグメントは予測期間中に最も速いCAGRで成長すると予測されています。
• 動物別では、人獣共通感染症の増加、家畜人口の拡大、予防医療への関心の高まり、動物支出の増加により、2024年に生産動物セグメントが最大のシェアを占めました。
• ワクチンタイプ別では、牛用ワクチンセグメントが2024年に市場を独占し、予測期間中のCAGRは9.52%で最も急成長が見込まれます。
• 投与経路別では、経口剤セグメントが2024年にシェアで市場を独占しました。この成長は、業界各社がチュアブル錠などの新製品を発売したことに起因しています。しかし、局所投与セグメントは予測期間中に9.13%のCAGRで最速成長すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のアニマルヘルス市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
  • 市場の課題分析
• 米国のアニマルヘルス市場分析ツール
  • ポーターの分析
  • PESTEL分析
• COVID-19分析
• 主要国別のペット推定個体数

第4章 米国のアニマルヘルス市場：動物タイプの推定・動向分析

• セグメントダッシュボード
• 米国のアニマルヘルス市場変動分析
• 米国のアニマルヘルス市場規模と動向分析：動物タイプ別（2018年～2030年）
  • 生産動物
  • ペット

第5章 米国のアニマルヘルス市場：製品の推定・動向分析

• セグメントダッシュボード
• 米国のアニマルヘルス市場変動分析
• 米国のアニマルヘルス市場規模と動向分析：製品別（2018年～2030年）
  • 生物学的製剤
  • 医薬品
  • 医薬品飼料添加物

第6章 米国のアニマルヘルス市場：ワクチンタイプの推定・動向分析

• セグメントダッシュボード
• 米国のアニマルヘルス市場変動分析
• 米国のアニマルヘルス市場規模と動向分析：ワクチンタイプ別（2018年～2030年）
  • 牛用ワクチン
  • 豚用ワクチン
  • 家禽用ワクチン
  • 水産養殖用ワクチン
  • その他のワクチン

第7章 米国のアニマルヘルス市場：疾患の推定・動向分析

• セグメントダッシュボード
• 米国のアニマルヘルス市場変動分析
• 米国のアニマルヘルス市場規模と動向分析：疾患別（2018年～2030年）
  • 牛の病気
  • 豚の病気
  • 家禽の病気
  • 水産養殖関連の病気
  • その他の病気

第8章 米国のアニマルヘルス市場：投与経路の推定・動向分析

• セグメントダッシュボード
• 米国のアニマルヘルス市場変動分析
• 米国のアニマルヘルス市場規模と動向分析：投与経路別（2018年～2030年）
  • 経口
  • 注射
  • 局所
  • その他

第9章 米国のアニマルヘルス市場：流通チャネルの推定・動向分析

• セグメントダッシュボード
• 米国のアニマルヘルス市場変動分析
• 米国のアニマルヘルス市場規模と動向分析：流通チャネル別（2018年～2030年）
  • 小売
  • eコマース
  • 病院・クリニック薬局

第10章 競合情勢

• 市場参入企業の分類
• 企業市況分析/ヒートマップ分析
• 戦略マッピング
  • 合併と買収
  • パートナーシップとコラボレーション
  • その他
• 企業プロファイル
  • Zoetis Inc.
  • Ceva Sante Animale
  • Merck &Co., Inc.
  • Vetoquinol SA
  • Boehringer Ingelheim Gmbh
  • Elanco Animal Health Incorporated
  • Virbac
  • Phibro Animal Health Corporation
  • Dechra Pharmaceuticals Plc
  • Bimeda, Inc.
  • Cargill, Incorporated.
  • Aurora Pharmaceutical, Inc.
  • Calier

第11章 重要なポイント

List of Tables

• Table 1 Cost of surgeries, USD
• Table 2 Pricing analysis for vaccines (USD), 2024
• Table 3 Estimated animal population in U.S. by key species, 2018 to 2023
• Table 4 U.S. Animal Health Market Revenue Estimates and Forecast, By Product, 2018 - 2030 (USD Million)
• Table 5 U.S. Animal Health Market Revenue Estimates and Forecast, By Biologics, 2018 - 2030 (USD Million)
• Table 6 U.S. Animal Health Market Revenue Estimates and Forecast, By Vaccines, 2018 - 2030 (USD Million)
• Table 7 U.S. Animal Health Market Revenue Estimates and Forecast, By Pharmaceuticals, 2018 - 2030 (USD Million)
• Table 8 U.S. Animal Health Market Revenue Estimates and Forecast, By Animal Type, 2018-2030 (USD million)
• Table 9 U.S. Animal Health Market Revenue Estimates and Forecast, By Production Animal, 2018 - 2030 (USD Million)
• Table 10 U.S. Animal Health Market Revenue Estimates and Forecast, By Companion Animal, 2018 - 2030 (USD Million)
• Table 11 U.S. Animal Health Market Revenue Estimates and Forecast, By Type of Vaccine, 2018 - 2030 (USD Million)
• Table 12 U.S. Animal Health Market Revenue Estimates and Forecast, By Disease, 2018 - 2030 (USD Million)
• Table 13 U.S. animal health market estimates and forecast, by Route of administration, 2018 - 2030 (USD Million)
• Table 14 U.S. Animal Health Market Revenue Estimates and Forecast, By Injectables, 2018 - 2030 (USD Million)
• Table 15 U.S. Animal Health Market Revenue Estimates and Forecast, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Participants' overview
• Table 17 Financial performance
• Table 18 Products benchmarking
• Table 19 Estimated Company Market Share in U.S Animal Health Market
• Table 20 Estimated Company Market Share in U.S Animal Health Pharmaceutical Market
• Table 21 Estimated Company Market Share in U.S Animal Health Vaccines Market
• Table 22 Estimated Company Market Share in the U.S Animal Health Medicated Feed Additives Market
• Table 23 Key market players initiating expansion
• Table 24 Key market players initiating mergers & acquisitions
• Table 25 Key market players initiating partnerships & collaborations.
• Table 26 Key market players initiating service launches/expansions
• Table 27 Key market players undertaking approvals
• Table 28 Key market players undertaking other activities
• Table 29 List of key market players

List of Figures

• Fig. 1 Market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 General methodology for Commodity flow analysis of Animal Health market
• Fig. 9 Commodity flow analysis
• Fig. 10 Segment-level bottom-up approach
• Fig. 11 Market snapshot
• Fig. 12 Segment snapshot
• Fig. 13 Segment snapshot
• Fig. 14 Segment snapshot
• Fig. 15 Competitive landscape snapshot
• Fig. 16 Parent market analysis, 2024 (USD billion)
• Fig. 17 Ancillary market outlook, 2024
• Fig. 18 U.S. animal health market dynamics
• Fig. 19 Estimated number of U.S. households owning a pet (2024)
• Fig. 20 U.S. animal health market: PORTER's analysis
• Fig. 21 U.S. animal health market: PESTEL analysis
• Fig. 22 U.S. Animal Health market by product type: Key takeaways
• Fig. 23 U.S. Animal Health market by product type market share, 2024 & 2030
• Fig. 24 Biologics market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Vaccines market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Attenuated vaccines market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Inactivated vaccines market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Subunit vaccines market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 29 DNA vaccines market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Recombinant vaccines market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Autogenous vaccines market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Other biologics market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Pharmaceuticals market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Parasiticides market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Anti-infectives market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Anti-inflammatory market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Analgesics market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Other market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Medicinal feed additives market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 40 U.S. animal health market by animal type: Key takeaways
• Fig. 41 U.S. animal health market by animal type market share, 2023 & 2030
• Fig. 42 Production animal market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Swine market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Poultry market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Cattle market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Sheep & goats market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Fish market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Companion animal market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Dogs market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Cats market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Horses market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Other market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 53 U.S. animal health market by type of vaccine: Key takeaways
• Fig. 54 U.S. animal health market by type of vaccine market share, 2024 & 2030
• Fig. 55 Cattle vaccine market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Porcine vaccine market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Poultry vaccine market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Aquaculture vaccine market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Other vaccines market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 60 U.S. animal health market by Disease: Key takeaways
• Fig. 61 U.S. animal health market by disease market share, 2024 & 2030
• Fig. 62 Porcine disease market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Poultry diseases market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Cattle diseases market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Aquaculture diseases market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Other diseases market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 67 U.S. animal health market by Route of administration: Key takeaways
• Fig. 68 U.S. animal health market by Route of administration, market share, 2024 & 2030
• Fig. 69 Oral market, 2018 - 2030 (USD Million)
• Fig. 70 Injectable market, 2018 - 2030 (USD Million)
• Fig. 71 Subcutaneous market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Intramuscular market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Intravenous market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Topical market, 2018 - 2030 (USD Million)
• Fig. 75 Other market, 2018 - 2030 (USD Million)
• Fig. 76 U.S. animal health market by distribution channel: Key takeaways
• Fig. 77 U.S. Animal Health market by distribution channel market share, 2024 & 2030
• Fig. 78 Retail market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 79 E-Commerce market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Hospital/Clinic Pharmacy market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Market participant categorization
• Fig. 82 Heat map analysis
• Fig. 83 Key strategies deployed by market players

U.S. Animal Health Market Growth & Trends:

The U.S. animal health market size is expected to reach USD 19.77 billion by 2030, registering a CAGR of 7.97% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, an increasing focus on preventative animal healthcare, advances in veterinary medicine, and rising R&D investment in veterinary pharmaceuticals to launch innovative products. For instance, in November 2024, Bimeda launched MoxiSolv Injection (moxidectin), an FDA-approved parasiticide for beef and non-lactating dairy cattle, in a convenient, non-shattering 500 mL plastic bottle.

Furthermore, the industry is also driven by rising incidences of zoonotic diseases, increased livestock population, growing focus on preventive care, and growing animal expenditure. The livestock population in the U.S. has increased, with significant growth in cattle, sheep, pigs, and poultry being raised for meat production. For instance, as of January 2024, the U.S. had 87.8 million cattle and 74.97 million swine stock, according to the U.S. Foreign Agricultural Service's Livestock and Poultry: World Markets and Trade report. This substantial livestock population necessitates comprehensive veterinary care and medical interventions to maintain health and productivity.

In addition, the economic significance of the cattle industry, which contributes over USD 70 billion annually, has driven stakeholders to prioritize health management to mitigate potential losses due to diseases. The rising consumer demand for high-quality beef and dairy products and growing awareness of sustainable farming practices have also played a crucial role in adopting health management solutions for cattle. Government-backed initiatives and enhanced veterinary services in rural areas further strengthen the sector, ensuring its continued expansion.

Additionally, increasing approval of medicated feed additives significantly drives the market by improving livestock health and production efficiency. For instance, in June 2024, The FDA approved Elanco's methane-reducing feed additive, Bovaer (3-NOP), for lactating dairy cattle. Bovaer can reduce methane emissions by 30% per cow, potentially lowering emissions equivalent to removing 285,000 cars from the road annually if used by one million cows. This innovation offers financial incentives for dairy farmers through carbon markets, supporting sustainability efforts and meeting global climate goals. In partnership with dsm-Firmenich, Elanco will market Bovaer across North America, contributing to sustainable farming practices and enhancing the dairy industry's competitiveness.

Similarly, rapid advancements in veterinary medicine present lucrative opportunities in the industry. Improvements in animal pharmaceuticals result in the development of more focused and efficient therapies for many kinds of animal illnesses and ailments. Furthermore, the demand for innovative veterinary medications is being driven by new drugs and therapies that provide better results for animals, decreased side effects, and increased efficacy. For instance, in September 2024, Merck Animal Health expanded its NOBIVAC NXT vaccine platform by launching NOBIVAC NXT FeLV, the first RNA vaccine for feline leukemia virus (FeLV). This innovative vaccine offers optimized protection against FeLV, a common feline infectious disease, and is expected to be available at veterinary clinics nationwide. Similarly, in June 2024, Bimeda launched Bimasone, the first FDA-approved generic flumethasone, used to treat inflammation and allergic conditions in horses, dogs, and cats.

U.S. Animal Health Market Report Highlights:

• Based on product, the pharmaceuticals segment accounted for the highest revenue share in 2024. However, the biologics segment is anticipated to grow at the fastest CAGR over the forecast period.
• Based on animals, the production animal segment held the largest share in 2024 owing to rising incidences of zoonotic diseases, increased livestock population, growing focus on preventive care, and increased animal expenditure.
• Based on the type of vaccine, the cattle vaccine segment dominated the market in 2024, and it is expected to grow fastest with a CAGR of 9.52% over the forecast period.
• Based on the route of administration, the oral segment dominated the market with a share in 2024. This growth can be attributed to new product launches such as chewable tablets by the industry players. However, the topical segment is anticipated to grow at the fastest CAGR of 9.13% over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Scope
  • 1.1.2. Estimates And Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis
  • 1.6.2. Global Market: CAGR Calculation
• 1.7. Research Scope and Assumptions
  • 1.7.1. List of Secondary Sources
  • 1.7.2. List of Primary Sources
  • 1.7.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Animal Health Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising Prevalence of Animal Diseases
    • 3.2.1.2. Growing Uptake Of Pet Insurance
    • 3.2.1.3. Increase In Pet Population & Pet Humanization
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Adverse effects associated with therapies
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. U.S. Animal Health Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal landscape
• 3.4. Covid-19 Analysis
• 3.5. Estimated Pet Population by key countries

Chapter 4. U.S. Animal Health Market: Animal Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Animal Health Market Movement Analysis
• 4.3. U.S. Animal Health Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
  • 4.3.1. Production Animals
    • 4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.2. Poultry
      • 4.3.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.3. Swine
      • 4.3.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.4. Cattles
      • 4.3.1.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.5. Sheep & Goats
      • 4.3.1.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.6. Fish
      • 4.3.1.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Companion Animals
    • 4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2.2. Dogs
      • 4.3.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2.3. Cats
      • 4.3.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2.4. Horses
      • 4.3.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2.5. Others
      • 4.3.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Animal Health Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Animal Health Market Movement Analysis
• 5.3. U.S. Animal Health Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 5.3.1. Biologics
    • 5.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.1.2. Vaccines
      • 5.3.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.1.2.2. Attenuated Live Vaccines
        • 5.3.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.1.2.3. Inactivated Vaccines
        • 5.3.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.1.2.4. Subunit Vaccines
        • 5.3.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.1.2.5. DNA Vaccines
        • 5.3.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 5.3.1.2.5.2. Recombinant Vaccines
        • 5.3.1.2.5.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 5.3.1.2.5.4. Autogenous Vaccines
        • 5.3.1.2.5.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 5.3.1.2.5.6. Other Biologics
        • 5.3.1.2.5.7. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. Pharmaceuticals
    • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.2. Parasiticides
      • 5.3.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.3. Anti-infectives
      • 5.3.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.4. Anti-inflammatory
      • 5.3.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.5. Analgesics
      • 5.3.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.6. Other Pharmaceuticals
      • 5.3.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Medicinal Feed Additives
    • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Animal Health Market: Type of Vaccine Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Animal Health Market Movement Analysis
• 6.3. U.S. Animal Health Market Size & Trend Analysis, by Type of Vaccine, 2018 to 2030 (USD Million)
  • 6.3.1. Cattle Vaccine
    • 6.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Porcine Vaccine
    • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Poultry Vaccine
    • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.4. Aquaculture Vaccine
    • 6.3.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.5. Other Vaccines
    • 6.3.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Animal Health Market: Disease Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Animal Health Market Movement Analysis
• 7.3. U.S. Animal Health Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 7.3.1. Cattle Disease
    • 7.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. Porcine Disease
    • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Poultry Disease
    • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Aquaculture Disease
    • 7.3.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Other Disease
    • 7.3.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Animal Health Market: Route of Administration Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Animal Health Market Movement Analysis
• 8.3. U.S. Animal Health Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 8.3.1. Oral
    • 8.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. Injectable
    • 8.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.2.2. Subcutaneous
      • 8.3.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.2.3. Intramuscular
      • 8.3.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.2.4. Intravenous
      • 8.3.2.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Topical
    • 8.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. Other
    • 8.3.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. U.S. Animal Health Market: Distribution Channel Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. U.S. Animal Health Market Movement Analysis
• 9.3. U.S. Animal Health Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 9.3.1. Retail
    • 9.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. E-Commerce
    • 9.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Hospital/ Clinic Pharmacy
    • 9.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
• 10.2. Company Market Position Analysis/ Heat Map Analysis
• 10.3. Strategy Mapping
  • 10.3.1. Mergers & Acquisitions
  • 10.3.2. Partnerships & Collaborations
  • 10.3.3. Others
• 10.4. Company Profiles
  • 10.4.1. Zoetis Inc.
    • 10.4.1.1. Participant's Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. Ceva Sante Animale
    • 10.4.2.1. Participant's Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. Merck & Co., Inc.
    • 10.4.3.1. Participant's Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. Vetoquinol S.A.
    • 10.4.4.1. Participant's Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Strategic Initiatives
  • 10.4.5. Boehringer Ingelheim Gmbh
    • 10.4.5.1. Participant's Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. Elanco Animal Health Incorporated
    • 10.4.6.1. Participant's Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. Virbac
    • 10.4.7.1. Participant's Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. Phibro Animal Health Corporation
    • 10.4.8.1. Participant's Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. Dechra Pharmaceuticals Plc
    • 10.4.9.1. Participant's Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. Bimeda, Inc.
    • 10.4.10.1. Participant's Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Strategic Initiatives
  • 10.4.11. Cargill, Incorporated.
    • 10.4.11.1. Participant's Overview
    • 10.4.11.2. Financial Performance
    • 10.4.11.3. Product Benchmarking
    • 10.4.11.4. Strategic Initiatives
  • 10.4.12. Aurora Pharmaceutical, Inc.
    • 10.4.12.1. Participant's Overview
    • 10.4.12.2. Financial Performance
    • 10.4.12.3. Product Benchmarking
    • 10.4.12.4. Strategic Initiatives
  • 10.4.13. Calier
    • 10.4.13.1. Participant's Overview
    • 10.4.13.2. Financial Performance
    • 10.4.13.3. Product Benchmarking
    • 10.4.13.4. Strategic Initiatives

Chapter 11. Key Takeaways